Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emmaus Life SciencesEMMA -1.72% Days Sales Outstanding is 19.91 as of Jun. 2026, which is 10% above its 10-year median of 18.13. The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Emmaus Life Sciences ranks better than 66.71% on this metric.
Emmaus Life Sciences (OTCPK:EMMA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Emmaus Life Sciences Days Sales Outstanding Related Terms
Emmaus Life Sciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs PCSA, LIMN, KAPA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Days Sales Outstanding falls into.
Emmaus Life Sciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a Days Sales Outstanding of 19.91 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Emmaus Life Sciences and its competitors. This is 10% above median its historical median of 18.13. Over the past decade, Emmaus Life Sciences' Days Sales Outstanding has ranged from 9.71 to 89.28. According to the industry distribution chart, Emmaus Life Sciences ranks #280 out of 841 companies in the Biotechnology industry, placing it in the top 33.3%.
Is Emmaus Life Sciences' Days Sales Outstanding too high?
Emmaus Life Sciences' current Days Sales Outstanding of 19.91 is 10% above median its 10-year median of 18.13. Over the past 10 years, this metric has ranged from a low of 9.71 to a high of 89.28. The Biotechnology industry median Days Sales Outstanding is 68.94. Emmaus Life Sciences' value of 19.91 is 71.1% below this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #280 out of 841 companies in the Biotechnology industry, which is above the industry midpoint.
How does Emmaus Life Sciences' Days Sales Outstanding compare to PCSA and LIMN?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #280 out of 841 companies for Days Sales Outstanding. This puts Emmaus Life Sciences in the upper half of its industry. The industry median Days Sales Outstanding is 68.94. Emmaus Life Sciences' value of 19.91 is 71.1% below this benchmark. Historically, Emmaus Life Sciences' own Days Sales Outstanding has ranged from 9.71 to 89.28 over the past decade. While the company's 10-year median is 18.13 vs. the industry median of 68.94, Emmaus Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Days Sales Outstanding of 19.91 is 71.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Days Sales Outstanding is 19.91, which is 10% above median its own 10-year median of 18.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.06 — trading 501.5% above its estimated fair value. The current Days Sales Outstanding is 19.91, which is 10% above median its 10-year median of 18.13 and 71.1% below the Biotechnology industry median of 68.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Days Sales Outstanding is 19.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 
